'Great Optimism' Over Complete Responses in dMMR Rectal Cancer - Medscape
A small trial shows that patients with locally advanced rectal cancer and deficient mismatch repair tumors respond remarkably well to neoadjuvant PD-1 blockade with dostarlimab.
Patients with locally advanced rectal cancer and tumors with deficient mismatch repair (dMMR) have shown a remarkable response to treatment with the programmed cell death-1 (PD-1) inhibitor dostarlim… [+6073 chars]
Read More
Other Stories in Health
- Dosa saree, Idli shirt and a pani puri watch? AI turns desi food into fashion
- Where and why men die younger: global data breaks it down
- 8 Best Foldable Rowing Machines, According to Editors and Certified Trainers
- Strawberry Lemon Cream Crepes {Grain-Free Options Included}
- What predicts belief in the afterlife? A massive global study has answers
- Getting active in midlife may boost brain resilience to Alzheimer’s
- May 2025 Cooking Challenge
- May 2025 Cooking Challenge
- TDP-43 dysfunction in brain blood vessels may drive Alzheimer's and ALS progression
.png)
